Loading...
688506 logo

Sichuan Biokin Pharmaceutical Co.,Ltd.SHSE:688506 Stock Report

Market Cap CN¥155.6b
Share Price
CN¥388.02
My Fair Value
CN¥315
23.3% overvalued intrinsic discount
1Y147.9%
7D16.0%
Portfolio Value
View

Sichuan Biokin Pharmaceutical Co.,Ltd.

SHSE:688506 Stock Report

Market Cap: CN¥155.6b

Sichuan Biokin PharmaceuticalLtd (688506) Stock Overview

Engages in the research and development, production, and marketing of small molecule chemical, molecular biological, and antibody-drug conjugate drugs in China and internationally. More details

688506 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

688506 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

US$5.30
FV
74.9% undervalued intrinsic discount
0%
Revenue growth p.a.
10users have liked this narrative
0users have commented on this narrative
45users have followed this narrative
Updated narrative

Sichuan Biokin Pharmaceutical Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sichuan Biokin PharmaceuticalLtd
Historical stock prices
Current Share PriceCN¥388.02
52 Week HighCN¥411.00
52 Week LowCN¥134.55
Beta1.03
1 Month Change30.03%
3 Month Change28.65%
1 Year Change147.87%
3 Year Changen/a
5 Year Changen/a
Change since IPO1,110.67%

Recent News & Updates

Recent updates

Here's What Analysts Are Forecasting For Sichuan Biokin Pharmaceutical Co.,Ltd. (SHSE:688506) After Its Annual Results

Apr 01
Here's What Analysts Are Forecasting For Sichuan Biokin Pharmaceutical Co.,Ltd. (SHSE:688506) After Its Annual Results

What Sichuan Biokin Pharmaceutical Co.,Ltd.'s (SHSE:688506) P/S Is Not Telling You

Feb 17
What Sichuan Biokin Pharmaceutical Co.,Ltd.'s (SHSE:688506) P/S Is Not Telling You

Does Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Have A Healthy Balance Sheet?

Dec 27
Does Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Have A Healthy Balance Sheet?

Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business

Nov 04
Solid Earnings Reflect Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Strength As A Business

Getting In Cheap On Sichuan Biokin Pharmaceutical Co.,Ltd. (SHSE:688506) Is Unlikely

Oct 29
Getting In Cheap On Sichuan Biokin Pharmaceutical Co.,Ltd. (SHSE:688506) Is Unlikely

Shareholder Returns

688506CN PharmaceuticalsCN Market
7D16.0%3.0%-1.6%
1Y147.9%48.4%49.8%

Return vs Industry: 688506 exceeded the CN Pharmaceuticals industry which returned 48.4% over the past year.

Return vs Market: 688506 exceeded the CN Market which returned 49.8% over the past year.

Price Volatility

Is 688506's price volatile compared to industry and market?
688506 volatility
688506 Average Weekly Movement7.7%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement5.1%
10% most volatile stocks in CN Market8.8%
10% least volatile stocks in CN Market3.0%

Stable Share Price: 688506's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 688506's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
19962,824Yi Zhuwww.baili-pharm.com

Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and marketing of small molecule chemical, molecular biological, and antibody-drug conjugate drugs in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines.

Sichuan Biokin Pharmaceutical Co.,Ltd. Fundamentals Summary

How do Sichuan Biokin PharmaceuticalLtd's earnings and revenue compare to its market cap?
688506 fundamental statistics
Market capCN¥155.60b
Earnings (TTM)-CN¥2.08b
Revenue (TTM)CN¥441.19m
352.7x
P/S Ratio
-74.9x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688506 income statement (TTM)
RevenueCN¥441.19m
Cost of RevenueCN¥262.81m
Gross ProfitCN¥178.38m
Other ExpensesCN¥2.26b
Earnings-CN¥2.08b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-5.18
Gross Margin40.43%
Net Profit Margin-470.73%
Debt/Equity Ratio109.2%

How did 688506 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/06 19:41
End of Day Share Price 2025/09/05 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sichuan Biokin Pharmaceutical Co.,Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shitong HanCitic Securities Co., Ltd.
Wenxin YuHaitong International Research Limited
Wen DaiHuatai Research